Artivion opened lower at $20.06, compared with its previous close of $20.10. In the last trading session, the stock traded between $19.20 and $20.77. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Artivion is now worth
$ 103.60
Giving a profit of
$ 3.60 (3.60%)
Invest with $1
Note: Past profits do not guarantee future returns.
Canaccord Genuity maintains a Buy rating on Artivion Inc. Price target lowered from $40 to $30 by analyst William Plovanic. Rating remains unchanged despite the $10 reduction in target.
6 days ago
6Nov
Artivion Q3FY26 Results: Revenue up 9% YoY, EBITDA declines 8%
Revenue rose 9% YoY to $123.8 million on a constant-currency basis. Adjusted EBITDA declined 8% to $22.5 million due to higher operating costs. Gross margin contracted 420 bps to 61.4% amid manufacturing investments. Full-year 2026 revenue guidance narrowed to 8-10% growth. Free cash flow turned negative at $17.6 million due to milestone payments.
7 days ago
20Oct
Jefferies initiates Buy rating on Artivion with $31 price target
Jefferies initiated coverage on Artivion with a Buy rating. Analyst Michael Sarcone assigned a price target of $31. The rating reflects a positive outlook on the company's performance.
23 days ago
7Aug
Artivion Latest Results: Sales guidance affirmed at $480.000M-$496.000M
Artivion confirms its FY2026 sales guidance remains unchanged at $480.000 million to $496.000 million. This range encompasses the market estimate of $486.232 million, reflecting stable revenue expectations for the fiscal year.
3mo ago
20Jul
Needham reiterates Buy on Artivion, maintains $44 price target
Needham analyst Mike Matson has reiterated a Buy rating for Artivion, maintaining a price target of $44.
3mo ago
29Jun
Artivion targets $150 million market with FDA approval for AMDS
Artivion Inc. received FDA PMA approval for its AMDS Hybrid Prosthesis to treat acute DeBakey Type I aortic dissections with malperfusion. The approval removes the previous requirement for institutional review board approval, facilitating faster patient access. Clinical data from the PERSEVERE trial indicated significant reductions in mortality and adverse events. Artivion estimates the device addresses a $150 million annual market opportunity in the U.S.
